Skip to main content
SpringerLink
Log in

Osteoporosemittel

  • Chapter
Arzneiverordnungs-Report 2007

  • 558 Accesses

Auszug

Hauptvertreter der Osteoporosemittel sind Bisphosphonate, die in der Onkologie auch dem Schutz vor Knochenmetastasen dienen. Leitsubstanz der Bisphosphonate ist Alendronsäure, auf die jetzt über 60% des Verordnungsvolumens dieser Stoffgruppe entfallen. Mit weitem Abstand folgen Raloxifen und Fluoridpräparate mit deutlich rückläufiger Tendenz. Kräftig angestiegen ist die Verordnung des 2004 eingeführten Strontiumranelat.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • American Medical Association (1986): Agents affecting calcium metabolism. In: Drug Evaluations, 6th ed, Saunders Company, Philadelphia, pp. 827–839, 885–902.

    Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2007): Empfehlungen zur Therapie und Prophylaxe der Osteoporose. Arzneiverordnung in der Praxis (Sonderheft 34S), 2. Auflage. Im Internet: www.akdae.de/35/83_Osteoporose_2007_2Auflage.pdf

    Google Scholar 

  • Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004): Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516–1525.

    Article  PubMed  CAS  Google Scholar 

  • Block GA, Raggi P, Bellasi A et al (2007): Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438–441.

    Article  PubMed  CAS  Google Scholar 

  • Bone HG, Hosking D, Devogelaer D et al (2004): Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189–1199.

    Article  PubMed  CAS  Google Scholar 

  • Dawson-Hughes B, Harris SS, Krall EA, Dallai GE (1997): Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337: 670–676.

    Article  PubMed  CAS  Google Scholar 

  • Djavan B, Thompson I, Michel MS, Waldert M, Scitz C (2004): Chemoprävention des Prostatakarzinoms. Urologe A 43: 557–561.

    Article  PubMed  CAS  Google Scholar 

  • Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (1999): Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282: 637–645.

    Article  PubMed  CAS  Google Scholar 

  • Fassbender WJ, Stumpf UC, Jockenhövel F (2006): Evidenzbasierte medikamentöse Therapie der Osteoporose. Med Klinik 101 Sondernr. 1: 178–181.

    Google Scholar 

  • Fleisch H (2000): Bisphosphonates in bone disease. From the laboratory to the patient. 4th ed, Academic Press, San Diego etc., pp. 1–212.

    Google Scholar 

  • Haguenauer D, Welch V, Shea B, Tugwell P, Wells G (2000): Fluoride for treating postmenopausal osteoporosis. Cochrane Database Syst Rev. 2000;(4): CD002825.

    Google Scholar 

  • Hersh AL, Stefanick ML, Stafford RS (2004): National use of postmenopausal hormone therapy. Annual trends and response to recent evidence. JAMA 291: 47–53.

    Article  PubMed  CAS  Google Scholar 

  • Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE et al; Women’s Health Initiative Investigators (2006): Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354: 669–683.

    Article  PubMed  CAS  Google Scholar 

  • Keaveny TM, Donley DW, Hoffmann PF et al (2007): Effects of teriporatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scars in women with osteoporosis. J Bone Miner Res 21: 149–157.

    Article  Google Scholar 

  • Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M (2007): Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant. 2007 Jun 25; [Epub ahead of print]

    Google Scholar 

  • Meunier PJ, Roux C, Seeman E et al (2004): The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350: 459–486.

    Article  PubMed  CAS  Google Scholar 

  • Mousny M, Bouse X, Wise L et al. (2006): The genetic influence on bone susceptibility to fluoride. Bone 39: 1283–1289.

    Article  PubMed  CAS  Google Scholar 

  • Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al (2001): Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441.

    Article  PubMed  CAS  Google Scholar 

  • NIH Consensus Conference (1994): Optimal calcium intake. JAMA 272: 1942–1948.

    Article  Google Scholar 

  • Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005): Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 90: 2816–2822.

    Article  PubMed  CAS  Google Scholar 

  • Riggs BL, O’Fallon WM, Lane A, Hodgson SF, Wahner HW et al (1994): Clinical trial of fluoride therapy in postmenopausal osteoporotic women: Extended observations and additional analysis. J Bone Miner Res 9: 265–275.

    Article  PubMed  CAS  Google Scholar 

  • Schousboe JT, Nyman JA, Kane RL, Eusrud KE (2005): Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 142: 734–741.

    PubMed  Google Scholar 

  • Silverberg SJ, Fairman C, Bilezikian JP et al (2004): Cinacalcet HCl effectively treats hypercalcemia in patients with parathyroid carcinoma (abstract no. SA495). J Bone Miner Res 19 Suppl. 1: S103.

    Google Scholar 

  • Suki W, Zabaneh R, Cangiano J, Reed J, Fischer D, Garrett L, Ling B, Chasan-Taber S, Dillon M, Blair A, Burke S (2006): A prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. The DCOR trial. Nephrol Dial Transplant 21(Suppl 4): 145–146.

    Google Scholar 

  • Wüster C, Ziegler R (1993): Fluorid-Therapie der Osteoporose: “Auf die Dosis kommt es an”. Dtsch Ärztebl 90: B–41–42.

    Google Scholar 

  • Ziegler R (2002): Osteoporose: aktuelle Diagnostik und Therapie. Orthopädische Praxis 38: 570–577.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

  2. Mozartstraße 20, 69121, Heidelberg

    Prof. Dr. med. h.c. Reinhard Ziegler

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. h.c. Reinhard Ziegler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK Schleswig-Holstein Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Schwabe, U., Ziegler, R. (2008). Osteoporosemittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_40

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-72548-0_40

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-72547-3

  • Online ISBN: 978-3-540-72548-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation